Abbott Laboratories 2014 Q2 10-Q Summary
Business Context and Reporting Period
Abbott Laboratories filed this unaudited Form 10-Q for the quarter and six months ended June 30, 2014. Abbott develops, manufactures, and sells health care products globally through Established Pharmaceutical Products, Nutritional Products, Diagnostic Products, Vascular Products, Diabetes Care, and Medical Optics. The filing reflects Abbott’s post-January 2013 separation from AbbVie.
Key Financial Metrics
| Metric | Three Months Ended June 30, 2014 | Three Months Ended June 30, 2013 | Six Months Ended June 30, 2014 | Six Months Ended June 30, 2013 |
|---|---|---|---|---|
| Net sales | $5,551 million | $5,446 million | $10,795 million | $10,824 million |
| Operating earnings | $761 million | $627 million | $1,212 million | $1,242 million |
| Earnings from continuing operations | $460 million | $476 million | $799 million | $1,021 million |
| Net earnings | $466 million | $476 million | $841 million | $1,021 million |
| Diluted EPS | $0.30 | $0.30 | $0.55 | $0.64 |
| Operating margin | 13.7% | 11.5% | 11.2% | 11.5% |
| Gross margin | 51.9% | 49.7% | 50.8% | 50.4% |
Quarterly sales increased 1.9% reported and 3.0% excluding foreign exchange. Six-month sales declined 0.3% reported but increased 1.8% excluding foreign exchange. International sales represented approximately 72% of second-quarter revenue and were negatively affected by the stronger U.S. dollar.
Six-month net cash from operating activities was $1.236 billion, compared with $1.177 billion in the prior-year period. Capital expenditures were $513 million, dividends paid were $676 million, and share repurchases were $2.193 billion. Management stated that annual operating cash flow is expected to exceed capital expenditures and cash dividends.
At June 30, 2014, cash and cash equivalents were $3.570 billion, short-term investments were $3.492 billion, and total debt was approximately $7.365 billion, including $3.953 billion of short-term borrowings, $9 million of current long-term debt, and $3.403 billion of long-term debt. Abbott had $5.0 billion of unused credit lines supporting commercial paper arrangements. Long-term debt ratings were A+ from Standard & Poor’s and A1 from Moody’s.
Material Changes Versus the Prior Comparable Period
- Second-quarter operating earnings increased 21%, primarily reflecting higher gross margins, lower intangible amortization, and lower restructuring costs.
- Six-month operating earnings declined 2%, while earnings from continuing operations declined 22%, primarily because of higher taxes and the absence of significant prior-year tax benefits.
- Second-quarter gross margin improved 220 basis points. Management attributed the improvement to resolution of an intellectual property matter that reduced vascular product costs, lower intangible amortization, and lower restructuring costs.
- Diagnostic Products revenue increased 4.8% in the quarter and 3.7% for the six months. Vascular Products operating earnings increased substantially, although drug-eluting stent sales declined.
- Established Pharmaceutical Products and Nutritional Products sales were affected by pricing pressure, foreign exchange, and the continuing effects of a 2013 supplier recall in certain international markets.
- Abbott repurchased 54.6 million shares for approximately $2.1 billion during the first six months and increased the quarterly dividend to $0.22 per share from $0.14.
Guidance, Outlook, Risks, Contingencies, and Unusual Items
- The filing does not provide a specific full-year earnings or revenue guidance range. Management expects operating cash flow to continue exceeding annual capital expenditures and cash dividends.
- On July 14, 2014, Abbott announced an agreement to transfer its developed-markets branded generics pharmaceutical business to Mylan in exchange for equity ownership in a newly formed entity. The transaction was valued at approximately $5.3 billion based on Mylan’s July 11 closing price, is expected to close in the first quarter of 2015, and is expected to be reported as discontinued operations beginning in the third quarter of 2014.
- Abbott agreed to acquire CFR Pharmaceuticals for approximately $2.9 billion, plus assumed net debt of approximately $430 million, with closing expected in the third quarter of 2014. It also agreed to acquire Veropharm for approximately $395 million to $495 million, plus assumed net debt of approximately $136 million, with closing expected in the fourth quarter. The acquisitions were expected to be funded with cash and short-term investments.
- First-half 2014 results included approximately $156 million of restructuring charges: $80 million for initiatives in vascular, diagnostics, and nutrition, and $76 million for other cost-reduction actions.
- Continuing-operations taxes included $58 million of benefits from prior-year tax matters; discontinued operations included $42 million of tax benefits related primarily to AbbVie’s pre-separation tax matters. Abbott said gross unrecognized tax benefits could decrease by up to $350 million within the next twelve months.
- Legal and environmental proceedings had an estimated possible loss range of approximately $65 million to $90 million, with an accrued balance of approximately $75 million at June 30, 2014. Management did not expect a material adverse effect, but outcomes remain uncertain.
- Key risks include foreign exchange volatility, health care regulation and reimbursement, intense competition, pricing pressure, supplier and product quality issues, litigation, tax audits, integration and execution risks related to acquisitions, and the pending Mylan transaction.
Most Important Facts for Investors to Verify
- Reconcile reported versus constant-currency sales growth and assess the continuing impact of foreign exchange.
- Evaluate whether the second-quarter margin improvement is sustainable after excluding the intellectual property resolution, lower amortization, and restructuring-related effects.
- Monitor the effects of the Mylan transaction, including the reclassification of developed-markets pharmaceuticals as discontinued operations.
- Assess funding capacity and balance-sheet effects from the CFR Pharmaceuticals and Veropharm acquisitions alongside share repurchases and dividends.
- Track the resolution of tax matters, including the potential reduction of up to $350 million in unrecognized tax benefits.
- Review exposure to nutritional product recall effects, vascular product competition, regulatory matters, litigation, and government health-care receivables in Southern Europe.